Loading…
The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases
Inositols are sugar-like compounds that are widely distributed in nature and are a part of membrane molecules, participating as second messengers in several cell-signaling processes. Isolation and characterization of inositol phosphoglycans containing myo- or d-chiro-inositol have been milestones fo...
Saved in:
Published in: | Biomedicines 2020-08, Vol.8 (9), p.295 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c542t-1af138739e7786c2c84d2f48a2d3663aa4dd8bf1b6a9923f256ae94fa03d759e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c542t-1af138739e7786c2c84d2f48a2d3663aa4dd8bf1b6a9923f256ae94fa03d759e3 |
container_end_page | |
container_issue | 9 |
container_start_page | 295 |
container_title | Biomedicines |
container_volume | 8 |
creator | López-Gambero, Antonio J. Sanjuan, Carlos Serrano-Castro, Pedro Jesús Suárez, Juan Rodríguez de Fonseca, Fernando |
description | Inositols are sugar-like compounds that are widely distributed in nature and are a part of membrane molecules, participating as second messengers in several cell-signaling processes. Isolation and characterization of inositol phosphoglycans containing myo- or d-chiro-inositol have been milestones for understanding the physiological regulation of insulin signaling. Other functions of inositols have been derived from the existence of multiple stereoisomers, which may confer antioxidant properties. In the brain, fluctuation of inositols in extracellular and intracellular compartments regulates neuronal and glial activity. Myo-inositol imbalance is observed in psychiatric diseases and its use shows efficacy for treatment of depression, anxiety, and compulsive disorders. Epi- and scyllo-inositol isomers are capable of stabilizing non-toxic forms of β-amyloid proteins, which are characteristic of Alzheimer’s disease and cognitive dementia in Down’s syndrome, both associated with brain insulin resistance. However, uncertainties of the intrinsic mechanisms of inositols regarding their biology are still unsolved. This work presents a critical review of inositol actions on insulin signaling, oxidative stress, and endothelial dysfunction, and its potential for either preventing or delaying cognitive impairment in aging and neurodegenerative diseases. The biomedical uses of inositols may represent a paradigm in the industrial approach perspective, which has generated growing interest for two decades, accompanied by clinical trials for Alzheimer’s disease. |
doi_str_mv | 10.3390/biomedicines8090295 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c46db138c4b84b7bb9c9410fde7cf27a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c46db138c4b84b7bb9c9410fde7cf27a</doaj_id><sourcerecordid>2436397144</sourcerecordid><originalsourceid>FETCH-LOGICAL-c542t-1af138739e7786c2c84d2f48a2d3663aa4dd8bf1b6a9923f256ae94fa03d759e3</originalsourceid><addsrcrecordid>eNptkkFvFCEUxydGY5vaT-CFxIuXrQwww-DBZG21blLrpT2TN_CYZTMLK8w0afzy4u6msUYuEPjl9x7_vKp6W9MLzhX90Pu4ReuND5g7qihTzYvqlDEmF4o26uVf55PqPOcNLUvVvKvF6-qEs441vGlPq193aySfjzIYyX3GTKIjqxCzn-KYP5IluZ2nBAbnaY8sd7sUwazJFMl3nKCPozfk6jG7OZjJx0B8IMvBh4FAsOQW5xQtDhgwweQfkFz5jFDqvKleORgznh_3s-r-65e7y2-Lmx_Xq8vlzcI0gk2LGlzpW3KFUnatYaYTljnRAbO8bTmAsLbrXd23oBTjjjUtoBIOKLeyUcjPqtXBayNs9C75LaRHHcHr_UVMg4ZU_jaiNqK1falmRN-JXva9MkrU1FmUxjEJxfXp4NrNfcnMYCjRjM-kz1-CX-shPmjZNEJSVQTvj4IUf86YJ7312eA4QsA4Z80Eb7mStRAFffcPuolzCiWqPaVY3dayUPxAmRRzTuiemqmp_jMr-j-zwn8D_oW17A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2436921617</pqid></control><display><type>article</type><title>The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases</title><source>Open Access: PubMed Central</source><source>ProQuest - Publicly Available Content Database</source><creator>López-Gambero, Antonio J. ; Sanjuan, Carlos ; Serrano-Castro, Pedro Jesús ; Suárez, Juan ; Rodríguez de Fonseca, Fernando</creator><creatorcontrib>López-Gambero, Antonio J. ; Sanjuan, Carlos ; Serrano-Castro, Pedro Jesús ; Suárez, Juan ; Rodríguez de Fonseca, Fernando</creatorcontrib><description>Inositols are sugar-like compounds that are widely distributed in nature and are a part of membrane molecules, participating as second messengers in several cell-signaling processes. Isolation and characterization of inositol phosphoglycans containing myo- or d-chiro-inositol have been milestones for understanding the physiological regulation of insulin signaling. Other functions of inositols have been derived from the existence of multiple stereoisomers, which may confer antioxidant properties. In the brain, fluctuation of inositols in extracellular and intracellular compartments regulates neuronal and glial activity. Myo-inositol imbalance is observed in psychiatric diseases and its use shows efficacy for treatment of depression, anxiety, and compulsive disorders. Epi- and scyllo-inositol isomers are capable of stabilizing non-toxic forms of β-amyloid proteins, which are characteristic of Alzheimer’s disease and cognitive dementia in Down’s syndrome, both associated with brain insulin resistance. However, uncertainties of the intrinsic mechanisms of inositols regarding their biology are still unsolved. This work presents a critical review of inositol actions on insulin signaling, oxidative stress, and endothelial dysfunction, and its potential for either preventing or delaying cognitive impairment in aging and neurodegenerative diseases. The biomedical uses of inositols may represent a paradigm in the industrial approach perspective, which has generated growing interest for two decades, accompanied by clinical trials for Alzheimer’s disease.</description><identifier>ISSN: 2227-9059</identifier><identifier>EISSN: 2227-9059</identifier><identifier>DOI: 10.3390/biomedicines8090295</identifier><identifier>PMID: 32825356</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Aging ; Alcohol ; Alzheimer's disease ; Antioxidants ; anxiety ; Brain research ; Clinical trials ; Cognitive ability ; Dementia ; Dementia disorders ; depression ; Diet ; Disease ; Down’s syndrome ; Functional foods & nutraceuticals ; Inositol ; Insulin ; Insulin resistance ; Isomers ; Kinases ; Mammals ; Mental disorders ; Metabolic disorders ; Neurodegenerative diseases ; Neuronal-glial interactions ; Obsessive compulsive disorder ; Oxidative stress ; Phosphoglycans ; psychiatric disease ; Review ; Second messengers ; Signal transduction ; Stereoisomers ; Sugar ; β-Amyloid</subject><ispartof>Biomedicines, 2020-08, Vol.8 (9), p.295</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c542t-1af138739e7786c2c84d2f48a2d3663aa4dd8bf1b6a9923f256ae94fa03d759e3</citedby><cites>FETCH-LOGICAL-c542t-1af138739e7786c2c84d2f48a2d3663aa4dd8bf1b6a9923f256ae94fa03d759e3</cites><orcidid>0000-0001-5254-9802 ; 0000-0002-4516-5795 ; 0000-0002-3414-2707 ; 0000-0001-7716-9056</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2436921617/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2436921617?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids></links><search><creatorcontrib>López-Gambero, Antonio J.</creatorcontrib><creatorcontrib>Sanjuan, Carlos</creatorcontrib><creatorcontrib>Serrano-Castro, Pedro Jesús</creatorcontrib><creatorcontrib>Suárez, Juan</creatorcontrib><creatorcontrib>Rodríguez de Fonseca, Fernando</creatorcontrib><title>The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases</title><title>Biomedicines</title><description>Inositols are sugar-like compounds that are widely distributed in nature and are a part of membrane molecules, participating as second messengers in several cell-signaling processes. Isolation and characterization of inositol phosphoglycans containing myo- or d-chiro-inositol have been milestones for understanding the physiological regulation of insulin signaling. Other functions of inositols have been derived from the existence of multiple stereoisomers, which may confer antioxidant properties. In the brain, fluctuation of inositols in extracellular and intracellular compartments regulates neuronal and glial activity. Myo-inositol imbalance is observed in psychiatric diseases and its use shows efficacy for treatment of depression, anxiety, and compulsive disorders. Epi- and scyllo-inositol isomers are capable of stabilizing non-toxic forms of β-amyloid proteins, which are characteristic of Alzheimer’s disease and cognitive dementia in Down’s syndrome, both associated with brain insulin resistance. However, uncertainties of the intrinsic mechanisms of inositols regarding their biology are still unsolved. This work presents a critical review of inositol actions on insulin signaling, oxidative stress, and endothelial dysfunction, and its potential for either preventing or delaying cognitive impairment in aging and neurodegenerative diseases. The biomedical uses of inositols may represent a paradigm in the industrial approach perspective, which has generated growing interest for two decades, accompanied by clinical trials for Alzheimer’s disease.</description><subject>Aging</subject><subject>Alcohol</subject><subject>Alzheimer's disease</subject><subject>Antioxidants</subject><subject>anxiety</subject><subject>Brain research</subject><subject>Clinical trials</subject><subject>Cognitive ability</subject><subject>Dementia</subject><subject>Dementia disorders</subject><subject>depression</subject><subject>Diet</subject><subject>Disease</subject><subject>Down’s syndrome</subject><subject>Functional foods & nutraceuticals</subject><subject>Inositol</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Isomers</subject><subject>Kinases</subject><subject>Mammals</subject><subject>Mental disorders</subject><subject>Metabolic disorders</subject><subject>Neurodegenerative diseases</subject><subject>Neuronal-glial interactions</subject><subject>Obsessive compulsive disorder</subject><subject>Oxidative stress</subject><subject>Phosphoglycans</subject><subject>psychiatric disease</subject><subject>Review</subject><subject>Second messengers</subject><subject>Signal transduction</subject><subject>Stereoisomers</subject><subject>Sugar</subject><subject>β-Amyloid</subject><issn>2227-9059</issn><issn>2227-9059</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkkFvFCEUxydGY5vaT-CFxIuXrQwww-DBZG21blLrpT2TN_CYZTMLK8w0afzy4u6msUYuEPjl9x7_vKp6W9MLzhX90Pu4ReuND5g7qihTzYvqlDEmF4o26uVf55PqPOcNLUvVvKvF6-qEs441vGlPq193aySfjzIYyX3GTKIjqxCzn-KYP5IluZ2nBAbnaY8sd7sUwazJFMl3nKCPozfk6jG7OZjJx0B8IMvBh4FAsOQW5xQtDhgwweQfkFz5jFDqvKleORgznh_3s-r-65e7y2-Lmx_Xq8vlzcI0gk2LGlzpW3KFUnatYaYTljnRAbO8bTmAsLbrXd23oBTjjjUtoBIOKLeyUcjPqtXBayNs9C75LaRHHcHr_UVMg4ZU_jaiNqK1falmRN-JXva9MkrU1FmUxjEJxfXp4NrNfcnMYCjRjM-kz1-CX-shPmjZNEJSVQTvj4IUf86YJ7312eA4QsA4Z80Eb7mStRAFffcPuolzCiWqPaVY3dayUPxAmRRzTuiemqmp_jMr-j-zwn8D_oW17A</recordid><startdate>20200820</startdate><enddate>20200820</enddate><creator>López-Gambero, Antonio J.</creator><creator>Sanjuan, Carlos</creator><creator>Serrano-Castro, Pedro Jesús</creator><creator>Suárez, Juan</creator><creator>Rodríguez de Fonseca, Fernando</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5254-9802</orcidid><orcidid>https://orcid.org/0000-0002-4516-5795</orcidid><orcidid>https://orcid.org/0000-0002-3414-2707</orcidid><orcidid>https://orcid.org/0000-0001-7716-9056</orcidid></search><sort><creationdate>20200820</creationdate><title>The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases</title><author>López-Gambero, Antonio J. ; Sanjuan, Carlos ; Serrano-Castro, Pedro Jesús ; Suárez, Juan ; Rodríguez de Fonseca, Fernando</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c542t-1af138739e7786c2c84d2f48a2d3663aa4dd8bf1b6a9923f256ae94fa03d759e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aging</topic><topic>Alcohol</topic><topic>Alzheimer's disease</topic><topic>Antioxidants</topic><topic>anxiety</topic><topic>Brain research</topic><topic>Clinical trials</topic><topic>Cognitive ability</topic><topic>Dementia</topic><topic>Dementia disorders</topic><topic>depression</topic><topic>Diet</topic><topic>Disease</topic><topic>Down’s syndrome</topic><topic>Functional foods & nutraceuticals</topic><topic>Inositol</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Isomers</topic><topic>Kinases</topic><topic>Mammals</topic><topic>Mental disorders</topic><topic>Metabolic disorders</topic><topic>Neurodegenerative diseases</topic><topic>Neuronal-glial interactions</topic><topic>Obsessive compulsive disorder</topic><topic>Oxidative stress</topic><topic>Phosphoglycans</topic><topic>psychiatric disease</topic><topic>Review</topic><topic>Second messengers</topic><topic>Signal transduction</topic><topic>Stereoisomers</topic><topic>Sugar</topic><topic>β-Amyloid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>López-Gambero, Antonio J.</creatorcontrib><creatorcontrib>Sanjuan, Carlos</creatorcontrib><creatorcontrib>Serrano-Castro, Pedro Jesús</creatorcontrib><creatorcontrib>Suárez, Juan</creatorcontrib><creatorcontrib>Rodríguez de Fonseca, Fernando</creatorcontrib><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Biomedicines</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>López-Gambero, Antonio J.</au><au>Sanjuan, Carlos</au><au>Serrano-Castro, Pedro Jesús</au><au>Suárez, Juan</au><au>Rodríguez de Fonseca, Fernando</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases</atitle><jtitle>Biomedicines</jtitle><date>2020-08-20</date><risdate>2020</risdate><volume>8</volume><issue>9</issue><spage>295</spage><pages>295-</pages><issn>2227-9059</issn><eissn>2227-9059</eissn><abstract>Inositols are sugar-like compounds that are widely distributed in nature and are a part of membrane molecules, participating as second messengers in several cell-signaling processes. Isolation and characterization of inositol phosphoglycans containing myo- or d-chiro-inositol have been milestones for understanding the physiological regulation of insulin signaling. Other functions of inositols have been derived from the existence of multiple stereoisomers, which may confer antioxidant properties. In the brain, fluctuation of inositols in extracellular and intracellular compartments regulates neuronal and glial activity. Myo-inositol imbalance is observed in psychiatric diseases and its use shows efficacy for treatment of depression, anxiety, and compulsive disorders. Epi- and scyllo-inositol isomers are capable of stabilizing non-toxic forms of β-amyloid proteins, which are characteristic of Alzheimer’s disease and cognitive dementia in Down’s syndrome, both associated with brain insulin resistance. However, uncertainties of the intrinsic mechanisms of inositols regarding their biology are still unsolved. This work presents a critical review of inositol actions on insulin signaling, oxidative stress, and endothelial dysfunction, and its potential for either preventing or delaying cognitive impairment in aging and neurodegenerative diseases. The biomedical uses of inositols may represent a paradigm in the industrial approach perspective, which has generated growing interest for two decades, accompanied by clinical trials for Alzheimer’s disease.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>32825356</pmid><doi>10.3390/biomedicines8090295</doi><orcidid>https://orcid.org/0000-0001-5254-9802</orcidid><orcidid>https://orcid.org/0000-0002-4516-5795</orcidid><orcidid>https://orcid.org/0000-0002-3414-2707</orcidid><orcidid>https://orcid.org/0000-0001-7716-9056</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2227-9059 |
ispartof | Biomedicines, 2020-08, Vol.8 (9), p.295 |
issn | 2227-9059 2227-9059 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_c46db138c4b84b7bb9c9410fde7cf27a |
source | Open Access: PubMed Central; ProQuest - Publicly Available Content Database |
subjects | Aging Alcohol Alzheimer's disease Antioxidants anxiety Brain research Clinical trials Cognitive ability Dementia Dementia disorders depression Diet Disease Down’s syndrome Functional foods & nutraceuticals Inositol Insulin Insulin resistance Isomers Kinases Mammals Mental disorders Metabolic disorders Neurodegenerative diseases Neuronal-glial interactions Obsessive compulsive disorder Oxidative stress Phosphoglycans psychiatric disease Review Second messengers Signal transduction Stereoisomers Sugar β-Amyloid |
title | The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A42%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Biomedical%20Uses%20of%20Inositols:%20A%20Nutraceutical%20Approach%20to%20Metabolic%20Dysfunction%20in%20Aging%20and%20Neurodegenerative%20Diseases&rft.jtitle=Biomedicines&rft.au=L%C3%B3pez-Gambero,%20Antonio%20J.&rft.date=2020-08-20&rft.volume=8&rft.issue=9&rft.spage=295&rft.pages=295-&rft.issn=2227-9059&rft.eissn=2227-9059&rft_id=info:doi/10.3390/biomedicines8090295&rft_dat=%3Cproquest_doaj_%3E2436397144%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c542t-1af138739e7786c2c84d2f48a2d3663aa4dd8bf1b6a9923f256ae94fa03d759e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2436921617&rft_id=info:pmid/32825356&rfr_iscdi=true |